

Research Article

New Proposal of Therapeutic Drug for Depression in Parkinson's Disease

Lourdes de Fatima Ibanez Valdes¹, Humberto Foyaca Sibat^{2*}

¹Department of Neurology, Walter Sisulu University (WSU), South Africa

²Department of Neurology, Nelson Mandela Academic Hospital, Walter Sisulu University, South Africa

*Address Correspondence to Humberto Foyaca Sibat, E-mail: humbertofoyacasibat@gmail.com

Received: 01 April 2026; Manuscript No: JDAR-26-171193; **Editor assigned:** 06 April 2026; PreQC No: JDAR-26-171193 (PQ); **Reviewed:** 21 April 2026; QC No: JDAR-26-171193; **Revised:** 15 May 2026; Manuscript No: JDAR-26-171193 (R); **Published:** 22 May 2026; DOI: 10.4303/JDAR/236513

Copyright: © 2026 Lourdes de Fatima Ibanez Valdes, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives: The main aim of this study is to discuss the latest information released into the medical literature regarding novel drug therapy of depression in Parkinson's disease.

Methods: A wide search of the medical literature of the following databases, PubMed/MEDLINE, Scopus, and Embase, was performed to find articles related to novel information on the pathogenesis of depression in PD.

From 01 January 2000 to 31 January 2026, we searched the medical literature following PRISMA guidelines. We searched Scopus, Embase, and PubMed Central using: "Pathogenesis of depression," "pathogenesis of Parkinson's disease," "novel treatment for depression," "gut-brain axis therapy," "dysbiosis," "limbic system," "major depressive disorders," "habenula dysfunction," "ibogaine" and "treatment of mood disorders".

Results: A literature search initially yielded 1563 articles. After removing 911 duplicates based on title and abstract review, 652 publications remained. Of these, 478 did not meet the inclusion/exclusion criteria, leaving 174 studies that investigated the pathogenesis of depression in PD. Among these, five manuscripts presented novel information on the treatment of depression in PD. However, quality assessment revealed that none of the selected articles delivered new hypotheses.

Keywords: Pathogenesis of depression; Pathogenesis of Parkinson's disease; Limbic system; Major depressive disorders; Dopaminergic dysfunction; Novel treatment of depression in PD

Abbreviations: 5-HT4R: Serotonin 4 Receptor; 6-OHDA: 6-hydroxydopamine; AHR: Aryl Hydrocarbon Receptor; ChAT: Choline Acetyltransferase; CNS: Central Nervous System; DHA: Docosahexaenoic Acid; DNs: Dopaminergic Neurons; DMV: Dorsal Motor Nucleus of the Vagus; ENS: Enteric Nervous System; FMT: Faecal Microbiota Transplantation; GDNF: Glial Cell Line-Derived Neurotrophic Factor; GF: Germ-Free; GFAP: Glial Fibrillary Acidic Protein; GLP-1: Glucagon-Like Peptide 1; GPR41: G-protein Coupled Receptor 41; HDAC: Histone Deacetylase; IPANs: Intrinsic Primary Afferent Neurons; LPS: Lipopolysaccharide; NaB: Sodium Butyrate; nNOS: neuronal Nitric Oxide Synthase; PD: Parkinson's Disease; PYY: Peptide YY; ROS: Reactive Oxygen Species; S100B: S100 calcium-binding protein B; SCFAs: Short-Chain Fatty Acids; TH: Tyrosine Hydroxylase; TLR: Toll-Like Receptor; TLR2: Toll-Like Receptor 2; TLR4: Toll-Like Receptor 4; TNF- α : Tumor Necrosis Factor Alpha; VIP: Vasoactive Intestinal Peptide

Introduction

In 1817, Dr. James Parkinson published his famous "Essay on the Shaking Palsy", in which he described the most relevant clinical features of this disease, which had been recognised since ancient times.

Motor symptoms such as tremor, rigidity, bradykinesia, and gait disturbance define PD. Meanwhile, non-motor symptoms, including sensory, autonomic, sleep, and psychiatric disturbances, are now defined as core features.

PD affects about 2% of people aged 65 and older worldwide. Its rising prevalence and earlier onset impose a significant socioeconomic burden [1-4]. This highlights the need for robust animal studies to model PD's molecular hallmarks and behavioural symptoms, and to clarify its pathogenesis and therapeutic strategies.

The underlying pathology of PD involves the gradual loss of dopamine-producing neurons in the substantia nigra, a region of the brain essential for movement and motivation, is particularly affected neurons degenerate, dopamine levels within the basal ganglia decline, leading to both motor and non-motor manifestations. A key pathological feature of this process is the accumulation of abnormal protein aggregates, known as Lewy bodies, composed of misfolded alpha-synuclein and contribute to ongoing neuronal dysfunction and cell death [5].

The motor symptoms of PD classically include resting tremor, rigidity, bradykinesia, and postural instability. Non-motor symptoms—such as depression, sleep disturbances, constipation, and cognitive impairment—are increasingly recognised as key components of the disease.

These symptoms often arise during the prodromal phase and often precede motor manifestations by several years. Non-motor symptoms, therefore, play a critical role in identifying individuals at risk of developing PD [6,7].

These non-motor symptoms may precede motor manifestations by several years and are therefore critical in the early identification of individuals at risk for PD [6,7].

In addition, non-motor symptoms majorly contribute to reduced quality of life and functional decline. Psychiatric manifestations, particularly depression, anxiety, and apathy, are especially important [7].

Depression, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR), is characterised by symptoms including depressed mood, anhedonia, feelings of guilt or worthlessness, impaired concentration, appetite changes, sleep disturbances, and recurrent thoughts of death [8].

In Parkinson's disease, however, the clinical presentation of depression often differs from that seen in primary Major Depressive Disorder (MDD). Although standard diagnostic criteria remain applicable, depressive symptoms in PD less commonly involve overt sadness, guilt, and suicidal ideation. Instead, they more often present as cognitive impairment, reduced motivation, and difficulties with concentration [9].

Symptoms less often include suicidal ideation, more often presenting as cognitive impairment, reduced motivation, and difficulty concentrating [9].

This distinction suggests that depression in Parkinson's disease may not merely represent a psychological response to chronic illness, but rather a manifestation of the underlying neurodegenerative process itself. Disruption of dopaminergic, serotonergic, and noradrenergic pathways, alongside the dysfunction of limbic and fronto-striatal circuits involved in mood regulation, it provides a biological basis for this altered clinical presentation [5].

In 2022, Weintraub and colleagues at the University of Pennsylvania reviewed Neuropsychiatric (NP) symptoms of Parkinson's disease. They found that these symptoms can cause as much disability as motor ones. They suggested specialised training, more research, greater awareness, and new care models to improve NP symptom management in Parkinson's disease.

The symptoms and signs of this complex NP disorder are characterised by perceptual and cognitive disturbances, such as psychosis; motivational symptoms, including apathy and impulse control disorders; and, most commonly, affective disturbances like anxiety and depression [10].

Non-Motor Symptoms (NMSs) of PD, described by James Parkinson almost 200 years ago, are integral to PD and worsen patients' quality of life. Moreover, their role was recognised as significant early in the characterisation of the disease.

It is a common neurodegenerative disorder characterised by progressive dopaminergic neuronal loss in the posterolateral aspect of the pars compacta in the substantia nigra and the deposition of α -synuclein (α -syn) aggregates, forming Lewy Bodies (LBs) and Lewy Neurites (LNs) [11, 12].

Depression and anxiety are quite common neuropsychiatric

disorders in PD, being more prevalent in PD than in the general population and other chronic conditions. Over 31% of people with PD had depressive symptoms associated with reduced quality of life [13].

Kim et al., proved the bidirectional relationship between depression/anxiety behaviours and α -synuclein (α -syn) propagation using A53T α -syn in an animal model subjected to chronic restraint stress and/or intrastriatal injection of α -syn preformed fibrils [14].

Parkinson's Disease (PD) is present worldwide, and the incidence and prevalence increase gradually with age. Epidemiologic investigations have also shown high rates. In 2016, 6.1 million people worldwide had PD (47.5% women and 52.5% men). This number was 2.4 times higher than in 1990 and was attributed to an increased population of older people, longer lifespans, longer disease duration, and environmental factors/exposures, among other factors. Nevertheless, prevalence rates were highest in high-income countries [15].

On the other hand, mood disturbances are quite common worldwide, affecting roughly 17.6% of the general population in any given year and approximately 29.2% of people over their lifetime. The most common are depression and anxiety, which might impact at least 600 million people globally [16].

The main aim of this review is to find out the novel reported information on therapeutic drug for depression in PD patients.

Materials and Methods

A comprehensive search of the medical literature in the PubMed/MEDLINE, Scopus, and Embase databases was conducted to identify articles reporting novel information on GA and diagnostic procedures.

The systematic review performed in this study followed the guidelines recommended by PRISMA (2020 statement).

Search strategy

From 01 January 2000 to 31 January 2026, we searched the medical literature following PRISMA guidelines. We searched the following issues: "Pathogenesis of depression," "pathogenesis of Parkinson's disease," "novel treatment for depression," "gut-brain axis therapy," "dysbiosis," "limbic system," "major depressive disorders," "habenula dysfunction," "ibogaine" and "treatment of mood disorders".

A systematic search was conducted across the following databases: PubMed Central/MEDLINE, Scopus, and Embase to identify publications on the pathophysiology of depression in PD and novel therapies.

Only articles published in English, Spanish and Portuguese were selected. Editorials, preclinical studies, and conference proceedings were excluded.

Selection of study

Both authors (LdeFIV, and HFS) separately reviewed the abstracts and titles of the selected publications

and independently reviewed the full-text versions of the identified articles to determine their eligibility for inclusion. Furthermore, publications without a clear protocol for confirmatory diagnosis, papers lacking analysis, publications with incomplete data, or those that did not mention the exact number of patients or treatment of depression and PD were not considered for inclusion.

Selection criteria

The following criteria were included: Articles with detailed pathogenesis and/or drug therapy. Clinical features of LIS and demographic information.

Exclusion criteria were applied:

- Inaccessibility to full text.
- Articles not affording drug therapy of depression in PD.
- Lack of relevant clinicopathological data.
- Non-original studies (*i.e.*, editorials, letters, conference proceedings, book chapters).
- Non-/Spanish/Portuguese/English studies.

The papers that were not thoroughly assessed were removed.

Data extraction and quality assessment

The studies' quality assessment, including applicability concerns and risk of bias, was categorised as good, poor, fair, or reasonable, in agreement with the National Institutes of Health criteria and The Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) evaluation. Quality evaluation was made separately by both authors, and disagreements were resolved by scientific discussion and final agreement.

Data collection, extraction, and bias assessment

All abstracts and titles with the inclusion criteria were

revised by two authors before being cited to collect relevant information for the review. For each publication selected in the review, data on the author's name, age, year of publication, country of the information source, type of study, total number of cases included, and treatment of depression in PD patients were collected. The selected data from eligible publications were entered into an updated Excel spreadsheet.

Outcome measures

Our plan was to select the most relevant publications on the therapy of depression in PD. This investigation also identified novel therapies for enteric nervous system disorder and pathogenesis of depression based on habenula dysfunction.

Statistical analysis

Statistical analysis was performed using XLSTAT (add-on for Microsoft Excel, version 2021.4.1, Addinsoft SARL and RStudio (version 4.3.1, <https://www.rstudio.com/>).

Results and Discussion

Literature search

Searching the literature retrieved 1563 articles. After reviewing the titles and abstracts, 911 duplicate publications were removed, leaving 652 publications selected. After applying the inclusion/exclusion criteria, 478 articles were excluded; therefore, 174 studies investigated the new therapy of depression in PD. Looking for novel information on the relationship among habenula dysfunction and depression in PD, 5 manuscripts were selected. For quality assessment, five articles that delivered new elements of pathogenesis were included (Figure 1).




Figure 1: PRISMA flow diagram with included publications

To provide an accurate assessment of this search, the authors used a QUADAS-2 evaluation to determine that the risk of bias was low/moderate for almost all publications. The authors considered the substantial technical differences observed across diagnostic protocols used in several

studies.

Noticeably, in some publications, small and mixed cohorts were processed, including different types of diagnostic procedures, leading to fewer cases examined under the same protocol.

Comments and final remarks

Predictors of depression, according to evidence from both cross-sectional and longitudinal studies, include factors such as psychiatric (*i.e.*, past or family history of depression, cognitive impairment, and rapid eye movement behaviour sleep disorder), demographic (*i.e.*, with female sex and younger age associated with increased severity of

depression), PD-related (*i.e.*, longer disease duration and motor fluctuations), and functional (*i.e.*, impaired activities of daily living and reduced physical activity) other non-motor (*i.e.*, constipation, pain, upper gastrointestinal symptoms, and fatigue) [17-19].

The commonest non-motor symptoms of PD are listed in Table 1.

Table 1: Frequency of most common non-motor symptoms. NMSs can also be classified according to their pathophysiology or drug therapy

Non-motor symptoms	NMS-Q Mean (%)	MDS_NMS Mean (%)
Urinary problems	74%	68%
Pain	65%	65%
Fatigue	64%	65%
Sleep problems	62%	63%
Constipation	48%	48%
Cognitive impairment	46%	48%
Depression/apathy	43%	39%
Excessive drooling	35%	33%

Psychosocial factors play a crucial role in the pathogenesis of depression in PD patients. Social connections, access to multidisciplinary care, spiritual well-being, and stable employment may be protective [20-22]. Related to impulse control disorders, there is combined evidence for its association with REM sleep disorder [23-25], low education level, male sex, older age, and cognitive impairment [26], mainly executive dysfunction [27]. The increasing severity of PD and depression is independently associated with the future occurrence of apathy [28,29].

Brief comments on drug therapy follow in this section

Unfortunately, only a small number of randomised controlled trials of antidepressants for depression have been performed [30].

For many decades, research on the neuropsychiatry of Parkinson's disease has focused on psychopharmacology, whereas non-pharmacological interventions (*e.g.*, psychotherapy or exercise) have received increased attention only since 2019 [31].

Alternative treatments for depression in PD include serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants.

However, no class has significantly impacted motor function, and rasagiline, a reversible selective monoamine oxidase B inhibitor, has shown poor benefits as monotherapy for PD depression [32-34].

Pramipexole might provide a mood benefit, although the effect size appears small. Despite new drugs such as nabilone (a synthetic cannabinoid) showing some alleviation of NP manifestation in PD, we believe that randomised controlled trials are needed before safe and confident administration.

Cognitive behavioural therapy (psychological intervention) for depression shows a beneficial effect in PD based on two randomised controlled trials of a telemedicine intervention performed by phone or web-based video conferencing, confirming statistically and clinically significant improvements compared with usual care [35,36].

On the other hand, repetitive transcranial magnetic stimulation for depression in PD has also delivered good results [37,38].

In cases presenting severe or refractory depression, electroconvulsive therapy has proven to be quite good and well tolerated in patients with PD, with the additional improvement of the clinical features of Parkinsonism [39]. Clinical classifications of NMSs of PD are listed in Table 2.

Table 2: Clinical classifications of NMSs of PD

Related to the disease process or pathophysiology	Dopaminergic, <i>e.g.</i> , depression, anxiety, dystonic pain and sleep disorders
	Non-dopaminergic, (cholinergic, serotonergic, noradrenergic, glutamatergic, and mixed) <i>e.g.</i> , hallucinations, urinary problems, cognitive impairment, neuropathic pain
Related to non-motor fluctuations	Present only during off periods, <i>e.g.</i> , mood disorders, impaired concentration
	Present during on periods and worse in off <i>e.g.</i> , pain, fatigue, constipation
Related to drug therapy for PD	<i>e.g.</i> , hallucinations, impulse control disorders, excessive daytime sleepiness
Genetically determined	Dementia or MCI in patients with glucocerebrosidase mutation
	Depression and sleep disorders in patients with LRRK-2 mutation

Other non-pharmacological treatments, such as various forms of aerobic training and bright light therapy, contributed positively to better outcomes of PD cases with depression.

Several forthcoming clinical trials for depression are still focusing on pharmacotherapy (for instance, on nortriptyline

and escitalopram), psychotherapy (interpersonal therapy and telehealth cognitive behavioural therapy), or brain stimulation (repetitive transcranial magnetic stimulation and transcranial direct current stimulation), as we listed in Table 3 the medical management of Parkinson disease and associated mood disorders [40,41].

Table 3: The medical management of Parkinson disease and associated mood disorders

Medication class	Examples	Primary indication	Key clinical considerations in PD + Mood disorders	Notable adverse effects/ Cautions
MAO-B inhibitors	Selegiline, rasagiline, safinamide	Motor symptom adjunct; mild antidepressant effect	Can be combined with levodopa; avoid combining with SSRIs/SNRIs due to serotonin syndrome risk	Insomnia, hypertension, serotonin syndrome (with serotonergic drugs)
Antidepressants (SSRIs)	Sertraline, citalopram, escitalopram, paroxetine	Depression, anxiety	First line for mood symptoms; generally motor-neutral	Worsened tremor in some cases, GI upset, hyponatremia, serotonin syndrome with MAO-B inhibitors
Dopamine agonists	Pramipexole, ropinirole, rotigotine	Motor symptom adjunct or monotherapy in early disease	Useful for reducing “off” time; may have mild antidepressant effect	Impulse-control disorders, hallucinations, somnolence, mania in bipolar patients
Dopaminergic therapy	Levodopa/carbidopa, benserazide/levodopa	Motor symptom control	First line for bradykinesia, rigidity, tremor; may modestly improve mood; adjust dosing gradually	Dyskinesia, nausea, orthostatic hypotension, hallucinations with long-term use
COMT inhibitors	Entacapone, opicapone, tolcapone	Prolong levodopa effect, reduce “off” periods	Improves motor fluctuations; adjust to minimize polypharmacy	Diarrhea, hepatotoxicity (tolcapone), dyskinesia
Antidepressants (SNRIs)	Venlafaxine, duloxetine	Depression, anxiety, pain	May improve energy and concentration; modest dopaminergic benefit	Tremor exacerbation, hypertension, withdrawal symptoms
Tricyclic antidepressants (TCAs)	Nortriptyline, desipramine	Depression (refractory cases)	Effective but use cautiously in older PD patients	Anticholinergic effects, arrhythmia, orthostatic hypotension
Atypical antipsychotics	Quetiapine, clozapine, pimavanserin	Psychosis, bipolar disorder	Quetiapine and clozapine are preferred due to minimal motor worsening; pimavanserin approved for PD psychosis	Sedation, orthostatic hypotension, agranulocytosis (clozapine), QT prolongation
Mood stabilizers	Lithium, valproate, lamotrigine	Bipolar disorder, mood stabilization	Lamotrigine preferred for minimal motor worsening; lithium/valproate may exacerbate tremor or rigidity	Tremor, ataxia, sedation, drug–drug interactions
Anxiolytics	Buspirone, clonazepam (RBD only)	Anxiety, REM sleep behavior disorder	Limited evidence for anxiety; clonazepam effective for RBD; avoid chronic benzodiazepine use	Sedation, falls, cognitive impairment, tolerance

Note: MAO-B: Monoamine Oxidase type B; COMT: Catechol-O-Methyltransferase; SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Serotonin–Norepinephrine Reuptake Inhibitor; RBD: REM Sleep Behavior Disorder.

Selective monoamine oxidase B inhibitors and antidepressants are often orally combined as part of the drug therapy for depression in PD patients, and adverse events have been reported from a randomised controlled trial [42] and a retrospective study [43], confirming that the risk for serotonin syndrome is low.

The distribution of different neurotransmitter along to some cerebral lobes are listed in table. Brief comments on microbial-based therapies for depression in PD Probiotics, which are “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host,”

have been confirmed to improve mental health symptoms live [44].

Other investigators reported that specific species within the *Lactobacillus* and *Bifidobacterium*. Genes exert the most important effect on alleviating mental health symptoms, particularly those associated with anxiety and depressive disorders. They also reported that consuming probiotics containing *Lactobacillus helveticus* and *Bifidobacterium longum* reduces anxiety levels and enhances overall mood [45].

Furthermore, *Bacillus coagulans* MTCC 5856 has been shown to improve sleep disturbances and significantly relieve depressive symptoms [46]. Notwithstanding, prebiotics, known as “non-digestible food components that selectively stimulate the growth and activity of beneficial microorganisms in the gut”, also provide a good effect on mental health [47-49].

A preclinical investigation reported that a fructo-oligosaccharide prebiotic can alleviate depression in a rat model [50]. Likewise, synbiotics, which combine prebiotics and probiotics, produce a synergistic effect on mental health outcomes [51].

Zang et al. found that a synbiotic combination, when used alongside fluoxetine, played a beneficial role in improving depression [52]. On top of that, many medical investigations have accurately shown improvements in symptoms of anxiety and depression after administrations of specific probiotic strains [53-55].

Brief comments on psychobiotics and next-generation probiotics

Psychobiotics are a type of probiotic that can provide benefits to cognition, mood, and behavioural responses, among other mental health functions, when administered at adequate and appropriate doses [56,57].

Therefore, psychobiotics represent a subset of probiotics characterised by their capacity to interact with the gut-brain

axis, modulating stress, mood, and overall mental well-being. Other authors reported that some types of strains of bacteria belonging to the *Streptococcus*, *Escherichia*, the genera *Lactobacillus*, *Bifidobacterium*, and *Enterococcus* can modulate GBA and improve mental health [58].

Other investigators have documented that psychobiotics alleviate depression and/or anxiety by enhancing mental well-being and overall mood [59].

The pharmacological function of psychobiotics is multifaceted, modulating 5-HT and GABA, reducing pro-inflammatory cytokines, and exerting remarkable control over the HPA axis, regulating stress responses, as has been confirmed by other investigators [60].

On top of that, some strains, such as *Lactobacillus plantarum* PS128 (psychobiotics), can improve dopamine metabolism and modulate norepinephrine production [61].

Brief comments on Faecal Microbiota Transplantation (FMT)

FMT is a medical procedure that reestablishes a balanced, healthy gut microbiota by introducing faecal material from a healthy donor into a recipient. After restoring microbial balance between Firmicutes and Bacteroidetes in the gut, it improves both gastrointestinal function and brain health [62,63]. Therapeutic strategies targeting microbial dopamine metabolism are shown in Figure 2.




Figure 2: The figure show faecal microbiota transplantation

FMT can more directly restructure microbial communities; pilot PD studies suggest safety and preliminary efficacy but require standardised, adequately powered trials before routine implementation [62,63].

Brief comments on the role of acupuncture in PD with depression

It has been shown that acupuncture increases BDNF, thereby improving neuronal function in patients with

depression by regulating miRNAs, modulating the p11/tPA/BDNF signalling axis, and enhancing miR-16 expression in the hippocampal formation and the median raphe nucleus. This procedure also increases BDNF levels to enhance neural plasticity, survival, NSC proliferation, and neuronal differentiation via BDNF downstream signalling, including PI3K/AKT, MAPK/ERK, and PLCγ, thereby alleviating depression (Figure 3) [64].




Figure 3: Therapeutic strategies targeting microbial dopamine metabolism

Neural activity in the basal ganglia, mainly the subthalamic nucleus, has been linked to depression in patients with PD. Nevertheless, the main role of the pallidum in its pathogenesis remains unknown. Because PD patients with severe depression symptoms have elevated beta (13–30 Hz) power compared to patients without depression and based on an association of depression with high beta (20–30 Hz) power, it has been considered that pallidal beta power is a potential biomarker of depression in PD, which supports Deep Brain Stimulation (DBS) therapy to improve depression in PD [65].

Therefore, DBS targeted to the Subthalamic Nucleus (STN) or the pallidum (specifically the Globus Pallidus internus (GPi)) is part of the treatment for PD cases presenting refractory motor symptoms and induces improvement in depression, mainly in the short term [66–68]. Liu and colleagues established a complex reciprocal association between depression/anxiety-like behaviours and A53T α -syn overexpression in PD. They also confirmed that CRS-induced affective disturbances worsen by α -syn propagation. Despite hyperactivity, A53T α -syn alone does not modify susceptibility to CRS-induced depressive behaviours in animals; the addition of PFF injection increases these behavioural phenotypes, highlighting the necessity of α -syn propagation for symptom aggravation. Therefore, there is a reciprocal association between depression-like behaviours and α -syn pathology in PD, and it seems that these factors interact dynamically, and their coexistence leads to worsening of the disease outcome [68]. On the other hand, modulation of c-Fos expression through the inhibitor T5224 mitigated both behavioural deficits and α -syn spread, suggesting its therapeutic effect on PD depression, while mGluR5 contributed to this interplay later, underscoring the central role of neuronal activity in enhancing quality of life [69].

Luk et al. reported that CRS facilitate α -syn propagation, suggesting PD progression, and accelerated PFF-induced dopaminergic neurodegeneration, while PFF administration alone did not cause significant loss of TH-positive neurons in the substantia nigra [70].

Although SSRIs and SNRIs are first-line choices for depression in PD, quetiapine or clozapine are strongly preferred to treat associated psychosis, which is necessary, plus non-pharmacologic therapies, including structured exercise, cognitive behavioural therapy, and patient–caregiver education, to enhance mood, function, and quality of life and diminish risks of side effects [71]. Other modalities of non-pharmacological interventions procedures are shown in table.

We highlighted structured exercise programs, including aerobic, resistance, and stretching exercises, plus physiotherapy, to provide additional reductions in psychological distress [72,73].

Additional comments on depression therapy in PD

As we cited before, Selective Serotonin Reuptake Inhibitors (SSRIs) such as citalopram, escitalopram, paroxetine, fluoxetine, and sertraline, as well as

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine, are confirmed as the first-line drugs to treat depression and anxiety. While, nortriptyline and desipramine (tricyclic antidepressants) have shown good efficacy in PD-related depression despite carrying a higher risk of orthostatic hypotension, anticholinergic side effects, and cardiac conduction abnormalities, mainly in older PD patients, being even worse in those cases with an associated autonomic dysfunction [71].

The same investigators recommended bupropion (norepinephrine–dopamine reuptake inhibitor) based on its dopamine-enhancing properties despite its side effect of enhancing tremors. Selegiline and rasagiline (MAO-B inhibitors) are quite good at controlling depressive symptoms in PD [74].

However, the combination of MAO-B inhibitors with SNRIs, SSRIs, or TCAs can increase the risk of serotonin syndrome [74–77].

It's quite important to consider that dopamine agonists and levodopa can exacerbate impulse-control disorders, psychosis and trigger mania in bipolar patients. van der Marck et al. reported that cases managed by a specialist multidisciplinary team showed remarkable improvements in quality of life, motor function, depression, and psychosocial functioning, and reduced caregiver strain, compared with those receiving only standard neurologist care [78].

Brief comments on gut microbiota-targeted therapies

PD is increasingly recognised as a gut-brain disorder [79].

Probiotics are gaining increasing attention in the treatment of neurodegenerative diseases, including the management of constipation in PD patients (Figure 3) [80].

Two independent groups of investigators have reported that *Lactobacillus reuteri* and *Bifidobacterium longum* can modulate electrophysiological effects on intestinal propulsion and enteric neurons, potentially enhancing motility effects relevant to PD [81,82].

And Brun et al., confirmed that *Saccharomyces boulardii* induces enteric neurodegeneration and inflammation in an experimental model of inflammatory bowel disease [83].

Collectively, these findings highlight probiotics as a promising strategy for modulating the ENS and gut microbiota in PD.

In PD animal models, FMT modulated intestinal permeability, prevented dopaminergic neuronal loss, altered microbiota composition, inhibited α -synuclein aggregation in the brain, and restored striatal neurotransmitter levels, thereby improving outcomes in PD patients [84,85].

Depression is the most common psychiatric disorder observed in Parkinson's Disease (PD) patients [86].

Brief comments on other therapeutic perspectives

Therapeutic strategies targeting microbial dopamine metabolism combine dietary approaches, selective enzyme inhibition, microbiota modulation, and precision

frameworks, moving toward mechanism-based, microbiome-informed care [87].

Ketamine is an NMDAR antagonist, classically used as an anaesthetic drug, which has a remarkable antidepressant effect [88-91].

Probiotics and prebiotics are the most feasible options; *Lactobacillus/Bifidobacterium* formulations improve quality of life and gastrointestinal symptomatology in PD [92].

High-fibre diets increase SCFA production, which can influence dopaminergic signalling, while polyphenol-rich diets may inhibit microbial decarboxylase activity involved in L-DOPA degradation [93,94].

Specific approaches integrating metabolomics, microbiome sequencing, and pharmacokinetics may enable stratified adjuncts (diet/probiotics/enzyme inhibition) aligned with individual microbial and metabolic profiles (Figure 3) [95-97].

Brief comments on modulating neuroplasticity

Neuroplasticity is the adaptive structural and functional reorganisation of neural circuits in response to physiological and environmental stimuli. Adult Hippocampal Neurogenesis (AHN)—characterised by the sustained proliferation, differentiation, and functional integration of newborn neurons within the dentate gyrus—constitutes a core mechanism of neural plasticity. This complex process begins with Neural Stem Cell (NSC) expression in the Subgranular Zone (SGZ), proceeds through neuroblast maturation, and culminates in the synaptic integration of granule cells into hippocampal circuits.

Therefore, AHN modulate cognitive and affective regulation, with its impairment directly linked to neuropsychiatric disorders, including depression [98,99].

Brief comments on psychedelic drug therapy

Psychedelic therapy (also known as psychedelic-assisted therapy) is a variety of mental health therapy that combines psychedelic substances with psychotherapy to address conditions like depression, administering MDMA, LSD, mescaline, psilocybin, DMT, and ibogaine. The last one has been used to treat neuropsychiatric disorders with good results by acting on NMDA receptors, the MHb-IPN axis, neurotrophic signalling, dopaminergic salience, and monoaminergic systems [101,102].

The pharmacokinetic mechanism of ibogaine differs from classical psychedelics, such as psilocybin and mescaline, because the latter two mainly exert their effects through serotonergic 5-HT_{2A} receptor agonism and do not directly modulate habenular nuclei or striatal dopaminergic signalling [102-105].

Noribogaine is the primary active metabolite of ibogaine, and both share a common indole alkaloid scaffold but differ by O-demethylation at the methoxy substituent (R=CH₃ for ibogaine; R=H for noribogaine).

Brief comments on the role of the habenula in the pathogenesis of depression in PD

The Habenula (Hb) from a phylogenetic point of view is part of the epithalamic structure and contains two nuclear complexes, the Lateral habenula (LHb) and the Medial (MHb) is located in the habenula triangle (in the posterior part of the diencephalon, just anterior to the pineal gland) and connects with the limbic system, with autonomic functions and emotional drives. It also integrates fronto-limbic and brainstem signals to regulate mood, motivation, and reward processing [106].

The Input and output connectivity pathways of the habenula to other regions are shown in Figure 4.




Figure 4: Shows a new hypotheses on the functional connectivity of the habenula through upregulate (U) and (D) downregulate connections with the following regions of the brain: 1. Medial septal group (Medial septal nuclei, Vertical diagonal band), 2. Nucleus basalis de Meynert, horizontal diagonal band of Broca, 3. Right amygdala (U), 4. Left parahippocampal gyrus (U), 5. Pontine cholinergic system (interpeduncular nuclei, laterodorsally tegmental nuclei, pedunculopontine tegmental nuclei, pontine reticular nuclei), 6. Dorsal Rafe nuclei, 7. Posterolateral aspect of pars compacta of substantia nigra, 8. Medial habenula nucleus, 9. Lateral hypothalamus, 10. Dorsolateral precentral frontal cortex, 11. Anterior cingulate cortex (D), 12. Right precentral gyri (U), 13. Right postcentral gyri (U/D), C: Cerebellum (D), T: Thalamus (D), VTA: Ventral Tegmental Area (D). All the elements working on the pathophysiology of dysfunctional habenula are listed in the middle of the figure and the chemical structure of the Ibogaine and noribogaine drugs working on those before-cited elements are also shown.

The MHb exerts a remarkable downregulation of Calcium-dependent Activator Protein for Secretion 2 (CAPS2) and deficits in nicotinic acetylcholine receptor-mediated signalling. On the other hand, LHb, dysregulated expression of the inward-rectifying potassium channel Kir4.1, Protein Phosphatase 2A (PP2A), the β isoform of Calcium/calmodulin-dependent protein kinase II (CaMKII β), and the small nucleolar RNA SNORA69 have been confirmed in animal models of depression. The left and right habenula nuclei are interconnected through the habenular commissure (white matter tract located on either side of the midline). The MHb is mainly composed of cholinergic neurons and substance P-ergic cells, characterised by small, round neurons densely packed together. The MHb predominantly receives cholinergic and Gamma-Aminobutyric Acid (GABA) inputs from the locus coeruleus, the diagonal band of Broca, the medial septum, and dopaminergic input from the Ventral Tegmental Area (VTA) and the superior cervical ganglion. Same authors reported that the Interpeduncular Nucleus (IPN), which is a structure located along the ventral midline of the midbrain, receives output from the MHb *via* the projection of the fasciculus retroflexus and it (IPN) projects to brainstem areas that regulate neurotransmitter production, including the VTA, the dorsal tegmental nucleus, and both dorsal and medial raphe nuclei. Moreover, MHb primarily receives signals from the septum (limbic system) and relays this information downstream to the brainstem *via* the IPN. The LHb receives input from the limbic system and the basal ganglia and regulates neurotransmission to the brainstem. *Via* glutamatergic projections, the LHb provides hyperexpression on GABAergic neurons in the RMTg, blocking dopaminergic neurons in the SNc and VTA, while also sending direct inputs to the VTA and DRN/MRN [106]. The same authors confirmed that disruptions in some proteins (ErbB4 and NRG1) in parvalbumin-positive neurons are involved in the development of depression.

Currently, the LHb activity is the main factor in the pathogenesis of major depressive disorder. Hb links basal forebrain structures with monoaminergic nuclei in the mid- and hindbrain, and it's involved in the regulation of the pars compacta of the substantia nigra dopamine release. On the other hand, LHb/MHb are interconnected with the median and dorsal raphe nucleus and play a crucial role in the pathogenesis of depression. We hypothesised that Ibogaine might exert a strong control on the Hb and may improve depression. Notwithstanding, ibogaine can also modulate opioid, glutamatergic, nicotinic, and monoaminergic systems, as well as neurotrophic signalling pathways, which are remarkably involved in synaptic plasticity and dopaminergic homeostasis [107,108].

Ibogaine administration modifies GDNF and BDNF expression in the cerebral areas involved in mesocorticolimbic and nigral dopaminergic circuits and plays an important role in the reconfiguration of addiction-related circuitry, accompanied by a window of enhanced plasticity that may facilitate sustained behavioural change [109].

Conclusion

We only found five articles affording new drugs therapeutic approach to depression in PD, but no one reported novel hypotheses regarding psychedelic drug therapy for depression in PD due to habenula dysfunction.

We hypothesised that the administration of ibogaine may contribute to modifying the habenular dysfunction leading to a better control of depression in PD. To the best of our knowledge, this is the first attempt to propose a novel therapeutic drug for depression in PD patients based on the correction of habenular disturbance by administering ibogaine. However, a well-designed randomised clinical trial must be done to prove or reject our hypotheses.

Acknowledgment

To thanks to Prof Thozama Dubula for his unconditional support.

Ethics Statement

This review does not require ethical approval.

Patient Privacy

All patient-identifying information has been removed to ensure anonymity.

Conflicts of Interest

Authors of this review report there is not conflicts of interest.

References

1. Parkinson J, An essay on the shaking palsy. 1817, J Neuropsychiatry Clin Neurosci, 14(2002):223-236.
2. J.W. Han, Y.D. Ahn, W.S. Kim, C.M. Shin, S.J. Jeong, et al. Psychiatric manifestation in patients with Parkinson's Disease, J Kor Med Sci, 33(2018).
3. D.K. Simon, C.M. Tanner, P. Brundin, Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med, 36(2020):1-12.
4. J. Zhao, Multidimensional mechanisms of anxiety and depression in Parkinson's disease: Integrating neuroimaging, neurocircuits, and molecular pathways, Pharmacol Res, 215(2025):107717.
5. M.H. Ahmad, Neurobiology of depression in Parkinson's disease: Insights into epidemiology, molecular mechanisms and treatment strategies, Ageing Res Rev, 85(2023):101840.
6. J.G. Goldman, R. Postuma, Premotor and nonmotor features of Parkinson's disease, Curr Opin Neurol, 27(2014):434-441.
7. N. Zhao, Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies, CNS Neuroscience and Therapeutics. Blackwell Publishing Ltd, (2021):270-279.
8. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. DSM-5-TR.

- Washington, DC: American Psychiatric Association Publishing, (2022).
9. R. Chikatimala, Depression in Parkinson's disease: A narrative review, *Cureus*, 14(2022):e27750.
 10. K.A. Jellinger, The pathobiological basis of depression in Parkinson disease: Challenges and outlooks. *J Neural Transm*, 129(2022):1397-1418.
 11. D. Weintraub, D. Aarsland, K.R. Chaudhuri, R.D. Dobkin, The neuropsychiatry of Parkinson's disease: Advances and challenges, *Lancet Neurol*, 21(2022):89-102.
 12. C. Cattaneo, A. Fabbrini, D. Belvisi, F. Aiello, F. Marchet, et al. Non-motor symptoms: The hidden face of Parkinson's disease, *Cells*, 15(2025):42.
 13. B. R. Bloem, M. S. Okun, C Klein, Parkinson's disease, *Lancet*, 397(2021):2284-2303.
 14. R. Uribe-Kirby, A. Pawlak, L. Pitman, G. Zuniga, J.D. Jones, Can we detect cognitive "super-agers" in Parkinson's disease? Cognitive, neuropsychiatric and motor outcomes in the first 10 years of Parkinson's disease, *Parkinsonism Relat Disord*, 133(2025):107345.
 15. S.J. Kim, J.B. Kim, S. Ham, S.M. Park, Uncovering the role of c-Fos in the bidirectional relationship between depression/anxiety behaviors and α -synuclein propagation in Parkinson's disease, *Neurotherapeutics*, 23(2025):e00807.
 16. Dorsey E.R., Elbaz A., Nichols E., Abd-Allah F., Abdelalim A., et al. Global, regional, and national burden of Parkinson's disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*, 17(2018):939-953.
 17. Z. Steel, C. Marname, C. Iranpour, T. Chey, J.W. Jackson, et al. The global prevalence of common mental disorders: A systematic review and meta-analysis 1980-2013, *Int J Epidemiol*, 43(2014):476-493.
 18. J. Marinus, K. Zhu, C. Marras, D. Aarsland, J.J. van Hilten, Risk factors for non-motor symptoms in Parkinson's disease, *Lancet Neurol*, 17(2018):559-568.
 19. M. Lubomski, R.L. Davis, C.M. Sue, Depression in Parkinson's disease: Perspectives from an Australian cohort, *J Affect Disord*, 277(2020):1038-1044.
 20. M. Siciliano, L. Trojano, G. Santangelo, R. De Micco, G. Tedeschi, et al. Fatigue in Parkinson's disease: A systematic review and meta-analysis, *Mov Disord*, 33(2018):1712-1723.
 21. R. Tuijt, A. Tan, M. Armstrong, J. Pigott, J. Read, et al. Self-management components as experienced by people with Parkinson's disease and their carers: A systematic review and synthesis of the qualitative literature, *Parkinsons Dis*, 2020(2020):8857385.
 22. J.K. Garlovsky, P.G. Overton, J. Simpson, Psychological predictors of anxiety and depression in Parkinson's disease: A systematic review, *J Clin Psychol*, 72(2016):979-998.
 23. J. Marín-Lahoz, F. Sampedro, S. Martinez-Horta, J. Pagonabarraga, J. Kulisevsky, Depression as a risk factor for impulse control disorders in Parkinson disease, *Ann Neurol*, 86(2019):762-69.
 24. H.T. Lu, Q.Y. Shen, Q.Z. Zhao, Association between REM sleep behavior disorder and impulsive-compulsive behaviours in Parkinson's disease: A systematic review and meta-analysis of observational studies, *J Neurol*, 267(2020):331-340.
 25. M.L. Fantini, J. Fedler, B. Pereira, D. Weintraub, A.R. Marques, et al. Is rapid eye movement sleep behavior disorder a risk factor for impulse control disorder in Parkinson disease? *Ann Neurol*, 88(2020):759-770.
 26. A. D'Iorio, G. Maggi, C. Vitale, L. Trojano, G. Santangelo, "Pure apathy" and cognitive dysfunctions in Parkinson's disease: A meta-analytic study, *Neurosci Biobehav Rev*, 94(2018):1-10.
 27. M.C. Wen, A. Thiery, W.I. Tseng, Apathy is associated with white matter network disruption and specific cognitive deficits in Parkinson's disease, *Psychol Med*, 52(2022):264-273.
 28. M.G. den Brok, J.W. van Dalen, W.A. van Gool, E.P. Moll van Charante, R.M. de Bie, et al. Apathy in Parkinson's disease: A systematic review and meta-analysis, *Mov Disord*, 30(2015):759-769.
 29. K.A. Mills, M.C. Greene, R. Dezube, C. Goodson, T. Karmarkar, et al. Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis, *Int J Geriatr Psychiatry*, 33(2018):642-651.
 30. K. Seppi, K. Ray Chaudhuri, M. Coelho, S.H. Fox, R. Katzenschlager, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review, *Mov Disord*, 34(2019):180-198.
 31. P. Barone, G. Santangelo, L. Morgante, M. Onofri, G. Meo, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients, *Eur J Neurol*, 22(2015):1184-1191.
 32. P. Barone, W. Poewe, S. Albrecht, C. Debieve, D. Massey, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial, *Lancet Neurol*, 9(2010):573-580.
 33. M. Peball, F. Krismer, H.G. Knaus, Non-motor symptoms in Parkinson's disease are reduced by nabilone, *Ann Neurol*, 88(2020):712-722.
 34. R.D. Dobkin, S.L. Mann, M.A. Gara, A. Interian,

- K.M. Rodriguez, et al. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial, *Neurology*, 94(2020):e1764-e1773.
35. R.D. Dobkin, S.L. Mann, D. Weintraub, Innovating Parkinson's care: A randomized controlled trial of telemedicine depression treatment, *Mov Disord*, 36(2021):2549-2558.
36. K. Seppi, K. Ray Chaudhuri, M. Coelho, Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review, *Mov Disord*, 34(2019):180-198.
37. S. Li, R. Jiao, X. Zhou, S. Chen, Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: A PRISMA-compliant meta-analysis, *Medicine (Baltimore)*, 99(2020):e19642.
38. A. Takamiya, M. Seki, S. Kudo, Electroconvulsive therapy for Parkinson's disease: A systematic review and meta-analysis, *Mov Disord*, 36(2021):50-58.
39. F. Lin, Y. Su, Y. Weng, X. Lin, H. Weng, et al. The effects of bright light therapy on depression and sleep disturbances in patients with Parkinson's disease: A systematic review and meta-analysis of randomized controlled trials, *Sleep Med*, 83(2021):280-289.
40. P.L. Wu, M. Lee, T.T. Huang, Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review, *PLoS One*, 12(2017):e0181515.
41. K.M. Smith, E. Eyal, D. Weintraub, Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: Effects on nonmotor symptoms and tolerability, *JAMA Neurol*, 72(2015):88-95.
42. E. Peña, C. Borrué, M. Mata, J.C. Martínez-Castrillo, A. Alonso-Canovas, et al. Impact of safinamide on depressive symptoms in Parkinson's disease patients (SADness-PD Study): A multicenter retrospective study, *Brain Sci*, 11(2021):232.
43. C. Hill, F. Guarner, G. Reid, G.R. Gibson, D.J. Merenstein, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, *Nat Rev Gastroenterol Hepatol*, 11(2014):506-514.
44. A. Dziedzic, K. Maciak, K. Bliźniewska-Kowalska, M. Gałęcka, W. Kobierecka, et al. The power of psychobiotics in depression: A modern approach through the microbiota-gut-brain axis: A literature review, *Nutrients*, 16(2024):1054.
45. M. Majeed, K. Nagabhushanam, S. Arumugam, S. Majeed, F. Ali, *Bacillus coagulans* MTCC 5856 for the management of major depression with irritable bowel syndrome: A randomised, double-blind, placebo controlled, multi-centre, pilot clinical study, *Food Nutr Res*, 62(2018).
46. V.O. Obayomi, A.F. Olaniran, O. Owa, Unveiling the role of functional foods with emphasis on prebiotics and probiotics in human health: A review, *J Funct Foods*, 119(2024):106337.
47. S. Yoo, S.C. Jung, K. Kwak, J.S. Kim, The role of prebiotics in modulating gut microbiota: Implications for human health, *Int J Mol Sci*, 25(2024).
48. D. Davani-Davari, M. Negahdaripour, I. Karimzadeh, M. Seifan, M. Mohkam, et al. Prebiotics: Definition, types, sources, mechanisms, and clinical applications, *Foods*, 8(2019).
49. L. Chi, I. Khan, Z. Lin, J. Zhang, M.Y.S. Lee, et al. Fructo-oligosaccharides from *Morinda officinalis* remodeled gut microbiota and alleviated depression features in a stress rat model, *Phytomedicine*, 67(2020):153157.
50. D.F. Gomez Quintero, C.R. Kok, R. Hutkins, The future of synbiotics: Rational formulation and design, *Front Microbiol*, 13(2022):919725.
51. Q. Zhang, B. Chen, J. Zhang, J. Dong, J. Ma, et al. Effect of prebiotics, probiotics, synbiotics on depression: Results from a meta-analysis, *BMC Psychiatry*, 23(2023):477.
52. A.C. Schaub, E. Schneider, J.F. Vazquez-Castellanos, N. Schweinfurth, C. Kettelhack, et al. Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: A randomized controlled trial, *Transl Psychiatry*, 12(2022):227.
53. A. Kazemi, A.A. Noorbala, K. Azam, M.H. Eskandari, K. Djafarian, Effect of probiotic and prebiotic vs. placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial, *Clin Nutr*, 38(2019):522-528.
54. H.J. Lee, J.K. Hong, J.K. Kim, D.H. Kim, S.W. Jang, et al. Effects of probiotic NVP-1704 on mental health and sleep in healthy adults: An 8-week randomized, double-blind, placebo-controlled trial, *Nutrients*, 13(2021):2660.
55. D. Zielińska, M. Karbowski, A. Brzezicka, The role of psychobiotics to ensure mental health during the COVID-19 pandemic-a current state of knowledge, *Int J Environ Res Public Health*, 19(2022):11022.
56. M. Del Toro-Barbosa, A. Hurtado-Romero, L.E. Garcia-Amezquita, T. García-Cayuela, Psychobiotics: Mechanisms of action, evaluation methods and effectiveness in applications with food products, *Nutrients*, 12(2020):3896.
57. V.O. Kyei-Baffour, A.K. Vijaya, A. Burokas, E.B.M. Daliri, Psychobiotics and the gut-brain axis: Advances in metabolite quantification and their implications for mental health, *Crit Rev Food Sci Nutr*, 65(2025):7085-

- 7104.
58. K. Ross, Psychobiotics: Are they the future intervention for managing depression and anxiety? A literature review, *Explore (NY)*, 19(2023):669–680.
59. R.F. Slykerman, N. Davies, K. Vlckova, K.J. O’Riordan, S.A. Bassett, et al. Precision psychobiotics for gut-brain axis health: Advancing the discovery pipelines to deliver mechanistic pathways and proven health efficacy, *Microb Biotechnol*, 18(2025):e70079.
60. J.F. Liao, Y.F. Cheng, S.W. Li, W.T. Lee, C.C. Hsu, et al. *Lactobacillus plantarum* PS128 ameliorates 2,5-Dimethoxy-4-iodoamphetamine-induced tic-like behaviors *via* its influences on the microbiota-gut-brain-axis, *Brain Res Bull*, 153(2019):59-73.
61. Z. Sahle, G. Engidaye, D.S. Gebreyes, B. Adenew, T.A. Abebe, Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond, *SAGE Open Med*, 12(2024).
62. M. Biazzo, G. Deidda, Fecal microbiota transplantation as new therapeutic avenue for human diseases, *J Clin Med*, 11(2022):4419.
63. J. Li, L. Liu, S. Sun, C. Liu, P. Yin, BDNF and miRNAs in acupuncture-regulated neuroplasticity: Emerging mechanisms and therapeutic strategies, *Medicine (Baltimore)*, 105(2026):e46851.
64. K.A. Johnson, P.B. Coutinho, L.E. Kenney, J.K. Wong, J.D. Hilliard, et al. Pallidal beta power is associated with depression in Parkinson’s disease, *NPJ Parkinsons Dis*, 12(2026):50.
65. M.I. Couto, A. Monteiro, A. Oliveira, N. Lunet, J. Massano, Depression and anxiety following deep brain stimulation in Parkinson’s disease: Systematic review and meta-analysis, *Acta Med Port*, 27(2014):372-382.
66. T. Cartmill, D. Skvarc, R. Bittar, J. McGillivray, M. Berk, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: A meta-analysis of mood effects, *Neuropsychol Rev*, 31(2021):385-401.
67. X. Liu, A. Geng, M. Xia, J. Lan, H. Wu, et al. Alterations in short-chain fatty acid-associated gut microbiota and tight junction integrity in adolescent major depressive disorder, *Transl Psychiatry*, 16(2025):11.
68. S.J. Kim, J.B. Kim, S. Ham, S.M. Park, Uncovering the role of c-Fos in the bidirectional relationship between depression/anxiety behaviors and α -synuclein propagation in Parkinson’s disease, *Neurotherapeutics*, 23(2025):e00807.
69. K.C. Luk, V.M. Kehm, B. Zhang, P. O’Brien, J.Q. Trojanowski, et al. Intracerebral inoculation of pathological α -synuclein initiates a rapidly progressive neurodegenerative α -synucleinopathy in mice, *J Exp Med*, 209(2012):975-986.
70. L.B. Dent, Diagnosis and management of Parkinson disease in individuals with pre-existing mood disorders, *Int J Environ Res Public Health*, 23(2026):269.
71. E. Angelopoulou, E. Stanitsa, C.C. Karpodini, A. Bougea, D. Kontaxopoulou, et al. Pharmacological and non-pharmacological treatments for depression in Parkinson’s disease: An updated review, *Medicina*, 59(2023):1454.
72. J.Y.Y. Kwok, J.C.Y. Kwan, M. Auyeung, V.C.T. Mok, C.K.Y. Lau, et al. Effects of mindfulness yoga vs. stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: A randomized clinical trial, *JAMA Neurol*, 76(2019):755-763.
73. K.A. Mills, M.C. Greene, R. Dezube, C. Goodson, T. Karmarkar, et al. Efficacy and tolerability of antidepressants in Parkinson’s disease: A systematic review and network meta-analysis, *Int J Geriatr Psychiatry*, 33(2018):642-651.
74. X.L. Wang, S.T. Feng, Y.T. Wang, B. Chen, Z.Z. Wang, et al. Comparative efficacy and acceptability of drug treatments for Parkinson’s disease with depression: A systematic review with network meta-analysis, *Eur J Pharmacol*, 927(2022):175070.
75. J. Liu, J. Dong, L. Wang, Y. Su, P. Yan, et al. Comparative efficacy and acceptability of antidepressants in Parkinson’s disease: A network meta-analysis, *PLoS One*, 8(2013):e76651.
76. G.M. Pontone, K.A. Mills, Optimal treatment of depression and anxiety in Parkinson’s disease, *Am J Geriatr Psychiatry*, 29(2021):530-540.
77. M.A. van der Marck, B.R. Bloem, G.F. Borm, S. Overeem, M. Munneke, et al. Effectiveness of multidisciplinary care for Parkinson’s disease: A randomized, controlled trial, *Mov Disord*, 28(2013):605-611.
78. L. Valdetaro, M.C. Ricciardi, P.P. Almeida, M.B. Stockler-Pinto, A.L. Tavares-Gomes, The enteric nervous system as a mediator of microbiota-gut-brain interactions in Parkinson’s disease, *J Neurochem*, 170(2026):e70339.
79. X. Jin, W. Dong, K. Chang, Y. Yan, X. Liu, Efficacy of probiotic supplements on Parkinson’s disease: A systematic review and meta-analysis, *Complement Ther Med*, 82(2024):103045.
80. B. Wang, Y.K. Mao, C. Diorio, L. Wang, J.D. Huizinga, et al. *Lactobacillus reuteri* ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurones, *Neurogastroenterol Motil*, 22(2010):98.
81. Khoshdel, E.F. Verdu, W. Kunze, P. McLean, G. Bergonzelli, J.D. Huizinga, *Bifidobacterium longum* NCC3001 inhibits AH neuron excitability, *Neurogastroenterol Motil*, 25(2013):e478-e484.

82. P. Brun, M. Scarpa, C. Marchiori, G. Sarasin, V. Caputi, et al. *Saccharomyces boulardii* CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS, *PLoS One*, 12(2017):e0181863.
83. M.F. Sun, Y.L. Zhu, Z.L. Zhou, X.B. Jia, Y.D. Xu, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF- α signaling pathway, *Brain Behav Immun*, 70(2018):48-60.
84. Z. Zhao, J. Ning, X.Q. Bao, M. Shang, J. Ma, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice *via* suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis, *Microbiome*, 9(2021):226.
85. X. Wen, X. Wu, J. Liu, K. Li, L. Yao, Abnormal baseline brain activity in non-depressed Parkinson's disease and depressed Parkinson's disease: A resting-state functional magnetic resonance imaging study, *PLoS One*, 8(2013):e63691.
86. A.H. Tan, J.W. Hor, C.W. Chong, S.Y. Lim, Probiotics for Parkinson's disease: Current evidence and future directions, *JGH Open*, 5(2020):414-419.
87. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, et al. Antidepressant effects of ketamine in depressed patients, *Biol Psychiatry*, 47(2000):351-354.
88. M.H. Chen, C.T. Li, W.C. Lin, C.J. Hong, P.C. Tu, et al. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study, *J Affect Disord*, 225(2018):709-714.
89. J.H. Krystal, E.T. Kavalali, L.M. Monteggia, Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms, *Neuropsychopharmacology*, 49(2024):41-50.
90. D. Matveychuk, R.K. Thomas, J. Swainson, A. Khullar, M.A. MacKay, et al. Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers, *Ther Adv Psychopharmacol*, 10(2020):2045125320916657.
91. F. Meiners, A. Ortega-Matienzo, G. Fuellen, I. Barrantes, Gut microbiome-mediated health effects of fiber and polyphenol-rich dietary interventions, *Front Nutr*, 12(2025):1647740.
92. N. Randeni, B. Xu, Critical review of the cross-links between dietary components, the gut microbiome, and depression, *Int J Mol Sci*, 26(2025):614.
93. H. Lee, A. Elkamhawy, P. Rakhalskaya, Q. Lu, H. Nada, et al. Small molecules in Parkinson's disease therapy: From dopamine pathways to new emerging targets, *Pharmaceuticals*, 17(2024):1688.
94. S.P. van Kessel, P. Auvinen, F. Scheperjans, S. El Aidy, Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease, *NPJ Parkinsons Dis*, 7(2021):115.
95. M.E. Abouelela, Y.A. Helmy, Next-generation probiotics as novel therapeutics for improving human health: Current trends and future perspectives, *Microorganisms*, 12(2024):430.
96. O.P.C. Ugwu, M.B. Okon, E.U. Alum, C.N.M. Ugwu, E.G. Anyanwu, et al. Unveiling the therapeutic potential of the gut microbiota-brain axis: Novel insights and clinical applications in neurological disorders, *Medicine*, 104(2025):e43542.
97. V.K. Sharma, P. Sharma, A. Mannan, S. Dhiman, M. Mohan, et al. Hippocampal neurogenesis: Bridging stress, cognitive decline, and therapeutic strategies for neural health, *Behav Brain Res*, 494(2025):115720.
98. M. Alonso, A.C. Petit, P.M. Lledo, The impact of adult neurogenesis on affective functions: Of mice and men, *Mol Psychiatry*, 29(2024):2527-2542.
99. C. Olash, D.M. Buchanan, R. Brown, A. Faerman, K. Cherian, et al. Accelerated recovery using magnesium ibogaine: Characterizing the subjective experience of its rapid healing from neuropsychiatric disorders, *NPJ Ment Health Res*, 5(2026):8.
100. M.P. Esperança, N.G.M. Gomes, M.G. Campos, Ibogaine: Therapeutic potential, cardiac safety, and translational perspectives in the treatment of substance use disorders-A scoping review, *Molecules*, 31(2026):545.
101. D.E. Nichols, Psychedelics, *Pharmacol Rev*, 68(2016):264-355.
102. R.L. Carhart-Harris, R. Leech, P.J. Hellyer, M. Shanahan, A. Feilding, et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs, *Front Hum Neurosci*, 8(2014):20.
103. C. Ly, A.C. Greb, L.P. Cameron, J.M. Wong, E.V. Barragan, et al. Psychedelics promote structural and functional neural plasticity, *Cell Rep*, 23(2018):3170-3182.
104. R.L. Carhart-Harris, K.J. Friston, REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics, *Pharmacol Rev*, 71(2019):316-344.
105. F. Lin, K. Casmey, S.A. Codeluppi-Arrowsmith, G. Turecki, The habenula's role in major depressive disorder: Recent insights from preclinical and human studies, *Transl Psychiatry*, 16(2026):77.
106. P. Popik, R.T. Layer, P. Skolnick, 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug, *Pharmacol Rev*, 47(1995):235-253.

-
- 107.D.Y. He, D. Ron, Autoregulation of glial cell line-derived neurotrophic factor expression: Implications for the long-lasting actions of the anti-addiction drug, ibogaine, *FASEB J*, 20(2006):2420-2422.
- 108.K.M. Velasquez, D.L. Molfese, R. Salas, The role of the habenula in drug addiction, *Front Hum Neurosci*, 8(2014):174.
- 109.S. Marton, B. González, S. Rodríguez-Bottero, E. Miquel, L. Martínez-Palma, et al. Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits, *Front Pharmacol*, 10(2019):193.